Canary Capital has registered a Delaware trust for a staked Injective ETF, marking an early step toward potentially launching a tradable INJ product in the U.S.
Canary Capital has established a trust for an exchange-traded fund offering exposure to staked Injective (INJ). The trust, named “Canary Staked INJ ETF,” was registered with the Delaware Division of Corporations and is designed to provide staking-based returns linked to the Injective blockchain.
While this filing does not guarantee the fund will launch, it follows the common path taken by many crypto ETF issuers.
A similar INJ product already exists in Europe, where asset manager 21Shares offers an Injective ETP that captures staking yield.
This move follows the firm’s earlier filing for a Staked Cronos (CRO) ETF in May, which aims to offer investors access to Cronos tokens and associated staking yields. The company is also awaiting a decision from the U.S. Securities and Exchange Commission on its proposed spot Sui (SUI) ETF, following a delayed response from the regulator earlier this month.
Additionally, Canary Capital recently registered a Delaware trust for a Staked Sei (SEI) ETF, marking an initial step toward launching a product that would offer investors exposure to SEI token staking rewards. Just days earlier, the firm submitted a Form S-1 for a Staked Tron (TRX) ETF, outlining similar staking mechanics.
Beyond these, Canary has also filed proposals for ETFs tied to Solana (SOL), Axelar (AXL), and Ripple (XRP), and has submitted a unique filing for an ETF tracking the Pudgy Penguins (PENGU) ecosystem—combining exposure to the PENGU governance token and associated NFTs.
